Future directions for new medical entities in osteoporosis

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 6, 2014, Pages 859-870

  Ferrari, Serge ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Blosozumab; Cathepsin K; Denosumab; Fractures; Odanacatib; Osteoporosis; PTHrP; Romosozumab; Sclerostin; Teriparatide

Indexed keywords

ABALOPARATIDE; BLOSOZUMAB; CATHEPSIN K; ODANACATIB; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; ROMOSOZUMAB; SCLEROSTIN; BIPHENYL DERIVATIVE; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; MONOCLONAL ANTIBODY; PARATHYROID HORMONE RELATED PROTEIN; SOST PROTEIN, HUMAN;

ARTICLE; BONE DENSITY; BONE STRUCTURE; BONE TURNOVER; DRUG EFFECT; HUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); TRABECULAR BONE; ANTAGONISTS AND INHIBITORS; GENETIC MARKER;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIPHENYL COMPOUNDS; BONE MORPHOGENETIC PROTEINS; CATHEPSIN K; GENETIC MARKERS; HUMANS; OSTEOPOROSIS; PARATHYROID HORMONE-RELATED PROTEIN;

EID: 84927618965     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2014.08.002     Document Type: Review

References (91)

1. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone 2011; 48: 677-92.
2. Boonen S, Ferrari S, Miller PD, et al. Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture riskea perspective. J Bone Miner Res 2012; 27: 963-74.
3. Matheny JB, Slyfield CR, Tkachenko EV, et al. Anti-resorptive agents reduce the size of resorption cavities: A threedimensional dynamic bone histomorphometry study. Bone 2013; 57: 277-83.
4. Dempster DW, Zhou H, Recker RR, et al. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: A randomized controlled trial. J Clin Endocrinol Metab 2012; 97: 2799-808.
5. Seeman E, Delmas PD. Bone qualityethe material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250-61.
6. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) . J Bone Miner Res 2012; 27: 243-54.
7. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX) : A randomized trial. Jama 2006; 296: 2927-38.
8. Seeman E, Delmas PD, Hanley DA, et al. Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate. J Bone Miner Res 2010; 25: 1886-94.
9. Yang L, Sycheva AV, Black DM, et al. Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: Results from the HORIZON Pivotal Fracture Trial. Osteoporos Int 2013; 24: 329-38.
10. Silverman SL, Chines AA, Kendler DL, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2011; 23: 351-63.
11. Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J Clin Endocrinol Metab 2013; 98: 4483-92.
12. Poole KE, Treece GM, Ridgway GR, et al. Targeted regeneration of bone in the osteoporotic human femur. PLoS One 2011; 6: E16190.
13. Borggrefe J, Graeff C, Nickelsen TN, et al. Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: Results from the EUROFORS study. J Bone Miner Res 2010; 25: 472-81.
14. Cooper C, Reginster JY, Cortet B, et al. Long-term treatment of osteoporosis in postmenopausal women: A review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF) . Curr Med Res Opin 2012; 28: 475-91.
15. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-15.
16. Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349: 1216-26.
17. Pierroz DD, Bonnet N, Baldock PA, et al. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 2010; 285: 28164-73.
18. Samadfam R, Xia Q, Goltzman D. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 2007; 22: 55-63.
19. Altman AR, Tseng WJ, de Bakker CM, et al. A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment. Bone 2014; 61: 149-57.
20. Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH (1-34) ] in postmenopausal osteoporosis. J Bone Miner Res 2011; 26: 503-11.
21. Leder BZ, Tsai JN, Uihlein AV, et al. Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study) : A randomized controlled trial. J Clin Endocrinol Metab 2014; 99: 1694-700.
22. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomised trial. Lancet 2013; 382: 50-6.
23. Cosman F. Combination therapy for osteoporosis: A reappraisal. BoneKEy Rep 2014; 3. Article No 518.
24. Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010; 95: 151-8.
25. Diaz R. Bone: Ronacaleret in osteoporosis. Nat Rev Endocrinol 2012; 8: 67.
26. Caltabiano S, Dollery CT, Hossain M, et al. Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women. Bone 2013; 56: 154-62.
27. Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al. Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women. J Bone Miner Res 2012; 27: 255-62.
28. Fitzpatrick LA, Dabrowski CE, Cicconetti G, et al. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2011; 96: 2441-9.
29. Bisello A, Chorev M, Rosenblatt M, et al. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J Biol Chem 2002; 277: 38524-30.
30. Ferrari SL, Bouxsein ML. Beta-arrestin-biased parathyroid hormone ligands: A new approach to the development of agents that stimulate bone formation. Sci Transl Med 2009; 1: 1.
31. Okazaki M, Ferrandon S, Vilardaga JP, et al. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A 2008; 105: 16525-30.
32. Dean T, Vilardaga JP, Potts Jr. JT, et al. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol 2008; 22: 156-66.
33. Pioszak AA, Parker NR, Gardella TJ, et al. Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides. J Biol Chem 2009; 284: 28382-91.
34. Soe K, Merrild DM, Delaisse JM. Steering the osteoclast through the demineralization-collagenolysis balance. Bone 2013; 56: 191-8.
35. Duong LT. Therapeutic inhibition of cathepsin K: Reducing bone resorption while maintaining bone formation. BoneKEy Rep 2012: 1.
36. Qing H, Ardeshirpour L, Pajevic PD, et al. Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res 2012; 27: 1018-29.
37. Wysolmerski J. Osteocytic osteolyis: Time for a second look. BoneKEy Rep 2012; 1. Article No 229.
38. Yates CJ, Bartlett MJ, Ebeling PR. An atypical subtrochanteric femoral fracture from pycnodysostosis: A lesson from nature. J Bone Miner Res 2011; 26: 1377-9.
39. Kundu ZS, Marya KM, Devgan A, et al. Subtrochanteric fracture managed by intramedullary nail in a patient with pycnodysostosis. Jt Bone Spine 2004; 71: 154-6.
40. Chavassieux P, Asser Karsdal M, Segovia-Silvestre T, et al. Mechanisms of the anabolic effects of teriparatide on bone: Insight from the treatment of a patient with pycnodysostosis. J Bone Miner Res 2008; 23: 1076-83.
41. Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 2009; 44: 199-207.
42. Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 2013; 123: 666-81.
43. Fuller K, Lawrence KM, Ross JL, et al. Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts. Bone 2008; 42: 200-11.
44. Guo J, Bot I, de Nooijer R, et al. Leucocyte cathepsin K affects atherosclerotic lesion composition and bone mineral density in low-density lipoprotein receptor deficient mice. Cardiovasc Res 2009; 81: 278-85.
45. Cheng XW, Kikuchi R, Ishii H, et al. Circulating cathepsin K as a potential novel biomarker of coronary artery disease. Atherosclerosis 2013; 228: 211-6.
46. Leung P, Pickarski M, Zhuo Y, et al. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 2011; 49: 623-35.
47. Masarachia PJ, Pennypacker BL, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 2012; 27: 509-23.
48. Pennypacker BL, Duong le T, Cusick TE, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 2011; 26: 252-62.
49. Cusick T, Chen CM, Pennypacker BL, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 2012; 27: 524-37.
50. Jerome C, Missbach M, Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. Osteoporos Int 2012; 23: 339-49.
51. Cabal A, Jayakar RY, Sardesai S, et al. High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate. Bone 2013; 56: 497-505.
52. Ochi Y, Yamada H, Mori H, et al. Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys. Bone 2014; 65: 1-8.
53. Runger TM, Adami S, Benhamou CL, et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 2012; 66: E89-96.
54. Nagase S, Hashimoto Y, Small M, et al. Serum and urine bone resorption markers and pharmacokinetics of the cathepsin K inhibitor ONO-5334 after ascending single doses in post menopausal women. Br J Clin Pharmacol 2012; 74: 959-70.
55. Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010; 25: 937-47.
56. Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: A randomized trial. J Clin Endocrinol Metab 2013; 98: 571-80.
57. Engelke K, Fuerst T, Dardzinski B, et al. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women - results of a 2-year placebo-controlled trial. J Bone Miner Res 2014.
58. Cheung AM, Majumdar S, Brixen K, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: Improvements in bone geometry, microarchitecture, and estimated bone strength. J Bone Miner Res 2014; 29: 1786-94.
59. Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: 5 years of continued therapy in a phase 2 study. J Bone Miner Res 2012.
60. Bonnick S, De Villiers T, Odio A, et al. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: A randomized placebo-controlled trial. J Clin Endocrinol Metab 2013; 98: 4727-35.
61. Eastell R, Nagase S, Ohyama M, et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study. J Bone Miner Res 2011; 26: 1303-12.
62. Eastell R, Nagase S, Small M, et al. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study. J Bone Miner Res 2014; 29: 458-66.
63. Engelke K, Nagase S, Fuerst T, et al. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: The OCEAN study. J Bone Miner Res 2014; 29: 629-38.
64. Ke HZ, Richards WG, Li X, et al. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012.
65. Robling AG, Niziolek PJ, Baldridge LA, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008; 283: 5866-75.
66. Kramer I, Keller H, Leupin O, et al. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab 2010; 21: 237-44.
67. Kramer I, Loots GG, Studer A, et al. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 2010; 25: 178-89.
68. Bonnet N, Conway SJ, Ferrari SL. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin. Proc Natl Acad Sci U S A 2012; 109: 15048-53.
69. Atkins GJ, Findlay DM. Osteocyte regulation of bone mineral: A little give and take. Osteoporos Int 2012.
70. Van Lierop A, Hamdy NA, van Bezooijen RL, et al. The role of sclerostin in the pathophysiology of sclerosing bone dysplasias. Clin Rev Bone Min Metab 2012; 10: 108-16.
71. Hassler N, Roschger A, Gamsjaeger S, et al. Sclerostin deficiency is linked to altered bone composition. J Bone Miner Res 2014.
72. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001; 68: 577-89.
73. Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 2005; 90: 6392-5.
74. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23: 860-9.
75. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009; 24: 578-88.
76. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010; 25: 2647-56.
77. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010; 25: 948-59.
78. Ominsky MS, Niu QT, Li C, et al. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody. J Bone Miner Res 2014; 29: 1424-30.
79. Spatz JM, Ellman R, Cloutier AM, et al. Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading. J Bone Miner Res 2013; 28: 865-74.
80. Sinder BP, Eddy MM, Ominsky MS, et al. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res 2013; 28: 73-80.
81. Roschger A, Roschger P, Keplingter P, et al. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone 2014; 66C: 182-8.
82. Hamann C, Rauner M, Hohna Y, et al. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res 2013; 28: 627-38.
83. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011; 26: 19-26.
84. McColm J, Hu L, Womack T, et al. Single-and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 2014; 29: 935-43.
85. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014; 370: 412-20.
86. Glantschnig H, Hampton RA, Lu P, et al. Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem 2010; 285: 40135-47.
87. Henriksen DB, Alexandersen P, Hartmann B, et al. Disassociation of bone resorption and formation by GLP-2: A 14-day study in healthy postmenopausal women. Bone 2007; 40: 723-9.
88. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: Now and the future. Lancet 2011; 377: 1276-87.
89. Henriksen DB, Alexandersen P, Hartmann B, et al. Four-month treatment with GLP-2 significantly increases hip BMD: A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone 2009; 45: 833-42.
90. Monami M, Dicembrini I, Antenore A, et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: A meta-analysis of randomized clinical trials. Diabetes Care 2011; 34: 2474-6.
91. Lewiecki EM, Cummings SR, Cosman F. Treat-to-target for osteoporosis: Is now the time? J Clin Endocrinol Metab 2013; 98: 946-53.